Investigational drug · Phase 3
Stapokibart
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Seasonal Allergic Rhinitis (SAR), Bullous Pemphigoid (BP), Prurigo Nodularis.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
14
Any phase or sponsor naming "Stapokibart"
First trial start
2024
Jun 25, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Stapokibart", any sponsor or status.
Conditions studied
As listed on its trial records.
- Seasonal Allergic Rhinitis (SAR)
- Bullous Pemphigoid (BP)
- Prurigo Nodularis
Approved drugs for the same conditions: Allergies (allergic rhinitis)
Largest trials
Live from ClinicalTrials.gov: studies naming "Stapokibart" as an intervention, largest first.
Chengdu Kangnuoxing Biopharma,Inc.Industry
NCT07544862 · 1,000 participants (planned) · Start Jun 2, 2026 · Primary completion Dec 2027
Drug: Stapokibart · For: Atopic Dermatitis (AD)
Sites: Beijing, China
- A Study of Stapokibart Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Active, not recruiting
Chengdu Kangnuoxing Biopharma,Inc.Industry
NCT07483268 · 600 participants (planned) · Start May 29, 2026 · Primary completion Dec 2027
Drug: Stapokibart · For: CRSWNP
Sites: Beijing, China
- A Prospective Study of Stapokibart Injection in Patients With Seasonal Allergic Rhinitis (SAR)Not yet recruiting
Chengdu Kangnuoxing Biopharma,Inc.Industry
NCT07459556 · 400 participants (planned) · Start Mar 2026 · Primary completion Dec 2027
Drug: Stapokibart · For: SAR
Sites: Beijing, China
- Study on the Treatment of Prurigo Nodularis With Stapokibart InjectionPivotal-lookingCompleted
Keymed Biosciences Co.LtdIndustry
NCT06424470 · 200 participants · Start Jun 25, 2024 · Primary completion Feb 11, 2026
Drug: Stapokibart · For: Prurigo Nodularis
Sites: Shenyang, China
- Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous PemphigoidPivotal-lookingNot yet recruiting
Chengdu Kangnuoxing Biopharma,Inc.Industry
NCT07210554 · 200 participants (planned) · Start Nov 11, 2025 · Primary completion Mar 27, 2028
Drug: Stapokibart injection; Placebo · For: Bullous Pemphigoid (BP)
Sites: Beijing, China
- Study on the Treatment of Adolescent Patients With Seasonal Allergic RhinitisPivotal-lookingRecruiting
Chengdu Kangnuoxing Biopharma,Inc.Industry
NCT07678931 · 136 participants (planned) · Start Aug 13, 2026 · Primary completion Dec 2026
Drug: Stapokibart; Placebo · For: Seasonal Allergic Rhinitis (SAR)
Sites: Beijing, China; Langfang, China; Baoding, China · 27 sites in all
- Study of Stapokibart Injection in Patients With Allergic RhinitisPivotal-lookingStatus unknown
Keymed Biosciences Co.LtdIndustry
NCT06525597 · 120 participants (planned) · Start Sep 30, 2024 · Primary completion Oct 30, 2025
Drug: Stapokibart Injection; Placebo · For: Allergic Rhinitis
Sites: Beijing, China
- A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal PolypsNot yet recruiting
Beijing Tongren HospitalAcademic, hospital or other
NCT06801353 · 90 participants (planned) · Start Feb 1, 2025 · Primary completion Dec 1, 2025
Drug: Stapokibart; Mometasone Furoate Nasal Spray (MFNS) · For: Chronic Rhinosinusitis with Nasal Polyps (CRSwNP); Biological Therapy; Biomarkers
Sites: Beijing, China
- Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia SyndromeNot yet recruiting
Huazhong University of Science and TechnologyAcademic, hospital or other
NCT07240376 · 90 participants (planned) · Start Nov 25, 2025 · Primary completion Dec 31, 2026
Drug: Stapokibart (CM310) · For: Non-Allergic Rhinitis With Eosinophilia Syndrome
Sites: Guangzhou, China; Wuhan, China; Xiangyang, China · 11 sites in all
- Preoperative Stapokibart for Endoscopic Sinus Surgery in Chronic Rhinosinusitis With Nasal PolypsNot yet recruiting
Beijing Tongren HospitalAcademic, hospital or other
NCT07616609 · 48 participants (planned) · Start Jun 1, 2026 · Primary completion Dec 31, 2028
Drug: Stapokibart; Matched placebo · For: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Stapokibart reduces blood eosinophil counts in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis from phase II and phase III clinical trials.
Zhao Y, Zhang F, Yang B, et al. · J Dermatolog Treat 2026
- Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trial.
Zhao Y, Zhang L, Wu L, et al. · J Dermatolog Treat 2026
- Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis: a network meta-analysis of phase 3-4 randomized trials.
Xiong M, Gao Q, Duan X · J Dermatolog Treat 2026
- Comment on "'Real-world outcomes of stapokibart-based combination therapy for bullous pemphigoid: a single-centre retrospective cohort': toward controlled comparisons, neurological profiling and long-term follow-up": reply from authors.
Wang SH, Liu SH, Zuo YG · Clin Exp Dermatol 2026
- Comment on 'Real-world outcomes of stapokibart-based combination therapy for bullous pemphigoid: a single-centre retrospective cohort': towards controlled comparisons, neurological profiling and long-term follow-up.
Xiao Y, Dong W, Zhu Y · Clin Exp Dermatol 2026
- Real-world outcomes of stapokibart-based combination therapy for bullous pemphigoid: a single-centre retrospective cohort.
Wang SH, Liu SH, Zhang J, et al. · Clin Exp Dermatol 2026
Also in development for Seasonal Allergic Rhinitis (SAR)
- ALDP001Phase 21 trial
Alixer Nexgen Therapeutics Limited · Seasonal Allergic Rhinitis (SAR)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.